These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 31880231)

  • 21. AMCP Guide to Pharmaceutical Payment Methods, 2009 Update (Version 2.0).
    Academy of Managed Care Pharmacy
    J Manag Care Pharm; 2009 Aug; 15(6 Suppl A):S3-57, quiz S58-61. PubMed ID: 19678720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget.
    Zaric GS; O'brien BJ
    Health Econ; 2005 Aug; 14(8):793-803. PubMed ID: 15685669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of financial incentives on the quality of health care provided by primary care physicians.
    Scott A; Sivey P; Ait Ouakrim D; Willenberg L; Naccarella L; Furler J; Young D
    Cochrane Database Syst Rev; 2011 Sep; (9):CD008451. PubMed ID: 21901722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors associated with independent pharmacy owners' satisfaction with Medicare Part D contracts.
    Zhang S; Doucette WR; Urmie JM; Xie Y; Brooks JM
    Res Social Adm Pharm; 2010 Jun; 6(2):121-9. PubMed ID: 20511111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
    Falit BP; Singh SC; Brennan TA
    Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Misaligned Pharmacy Incentives in Value-Based Care.
    Jain N; Rome BN; Mendu ML
    JAMA; 2024 Jul; 332(4):281-282. PubMed ID: 38935387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding Payer Perspectives on Value in the Use of Pharmaceuticals in the United States.
    Brogan AP; Hogue SL; Vekaria RM; Reynolds I; Coukell A
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1319-1327. PubMed ID: 31778613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Use of Surrogate and Patient-Relevant Endpoints in Outcomes-Based Market Access Agreements : Current Debate.
    Toumi M; Jarosławski S; Sawada T; Kornfeld Å
    Appl Health Econ Health Policy; 2017 Feb; 15(1):5-11. PubMed ID: 27581118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Provider boycotts--a review of the Merck-Medco decision. Merck-Medco Managed Care L.L.C. v. Rite Aid Corporation.
    Becker S
    Health Care Law Mon; 2000 May; ():10-8. PubMed ID: 14743588
    [No Abstract]   [Full Text] [Related]  

  • 30. Arbitration Board Setting Reimbursement Amounts for Pharmaceutical Innovations in Germany When Price Negations between Payers and Manufacturers Fail: An Empirical Analysis of 5 Years' Experience.
    Ludwig S; Dintsios CM
    Value Health; 2016 Dec; 19(8):1016-1025. PubMed ID: 27987628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Carving in Pharmacy Benefits on Utilization and Costs.
    Parekh N; Papa S; Drnach A; Spiegel L; Huang Y; Manolis C; Good CB
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1317-1324. PubMed ID: 32996397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.
    Adamski J; Godman B; Ofierska-Sujkowska G; Osińska B; Herholz H; Wendykowska K; Laius O; Jan S; Sermet C; Zara C; Kalaba M; Gustafsson R; Garuolienè K; Haycox A; Garattini S; Gustafsson LL
    BMC Health Serv Res; 2010 Jun; 10():153. PubMed ID: 20529296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Specialty pharmacy management adjusts to new financial realities.
    Reinke T
    Manag Care; 2013 Apr; 22(4):13-4. PubMed ID: 23678558
    [No Abstract]   [Full Text] [Related]  

  • 34. Paying for Cures: How Can We Afford It? Managed Care Pharmacy Stakeholder Perceptions of Policy Options to Address Affordability of Prescription Drugs.
    Yeung K; Suh K; Basu A; Garrison LP; Bansal A; Carlson JJ
    J Manag Care Spec Pharm; 2017 Oct; 23(10):1084-1090. PubMed ID: 28944726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Policy Recommendations for Pharmacy Benefit Managers to Stem the Escalating Costs of Prescription Drugs: A Position Paper From the American College of Physicians.
    Daniel H; Bornstein SS;
    Ann Intern Med; 2019 Dec; 171(11):823-824. PubMed ID: 31711103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement.
    Neumann PJ; Chambers JD; Simon F; Meckley LM
    Health Aff (Millwood); 2011 Dec; 30(12):2329-37. PubMed ID: 22147861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A primer on brand-name prescription drug contracting.
    Kenney JT; Keast S
    J Manag Care Spec Pharm; 2024 May; 30(5):507-513. PubMed ID: 38651983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Private sector risk-sharing agreements in the United States: trends, barriers, and prospects.
    Garrison LP; Carlson JJ; Bajaj PS; Towse A; Neumann PJ; Sullivan SD; Westrich K; Dubois RW
    Am J Manag Care; 2015 Sep; 21(9):632-40. PubMed ID: 26618366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paying for Performance Improvement in Quality and Outcomes of Cardiovascular Care: Challenges and Prospects.
    Husaini M; Joynt Maddox KE
    Methodist Debakey Cardiovasc J; 2020; 16(3):225-231. PubMed ID: 33133359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Public payers foot greater pharmacy costs.
    Manag Care; 2006 Jul; 15(7):70. PubMed ID: 16898070
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.